2018 Q2 Form 10-Q Financial Statement
#000156459018021470 Filed on August 13, 2018
Income Statement
| Concept | 2018 Q2 | 2017 Q2 |
|---|---|---|
| Revenue | $172.0K | $0.00 |
| YoY Change | ||
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $2.220M | $990.0K |
| YoY Change | 124.24% | |
| % of Gross Profit | ||
| Research & Development | $5.414M | $3.320M |
| YoY Change | 63.07% | |
| % of Gross Profit | ||
| Depreciation & Amortization | $195.0K | $100.0K |
| YoY Change | 95.0% | 25.0% |
| % of Gross Profit | ||
| Operating Expenses | $7.644M | $4.413M |
| YoY Change | 73.22% | |
| Operating Profit | -$7.472M | -$4.413M |
| YoY Change | 69.32% | |
| Interest Expense | $170.0K | $0.00 |
| YoY Change | ||
| % of Operating Profit | ||
| Other Income/Expense, Net | $172.0K | |
| YoY Change | ||
| Pretax Income | -$7.300M | -$4.410M |
| YoY Change | 65.53% | |
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | -$7.300M | -$4.413M |
| YoY Change | 65.42% | |
| Net Earnings / Revenue | -4244.19% | |
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$358.2K | -$194.7K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 20.13M | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2018 Q2 | 2017 Q2 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $45.80M | $7.400M |
| YoY Change | 518.92% | |
| Cash & Equivalents | $45.94M | $7.307M |
| Short-Term Investments | $100.0K | $100.0K |
| Other Short-Term Assets | $3.500M | $900.0K |
| YoY Change | 288.89% | |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | ||
| Other Receivables | ||
| Total Short-Term Assets | $49.25M | $8.200M |
| YoY Change | 500.61% | |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $2.763M | $1.700M |
| YoY Change | 62.53% | |
| Goodwill | ||
| YoY Change | ||
| Intangibles | $175.0K | |
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $900.0K | $200.0K |
| YoY Change | 350.0% | |
| Total Long-Term Assets | $3.864M | $2.000M |
| YoY Change | 93.2% | |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $49.25M | $8.200M |
| Total Long-Term Assets | $3.864M | $2.000M |
| Total Assets | $53.11M | $10.20M |
| YoY Change | 420.73% | |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $546.0K | $800.0K |
| YoY Change | -31.75% | |
| Accrued Expenses | $1.124M | $700.0K |
| YoY Change | 60.57% | |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $2.963M | $1.600M |
| YoY Change | 85.19% | |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Other Long-Term Liabilities | $0.00 | |
| YoY Change | ||
| Total Long-Term Liabilities | $0.00 | $0.00 |
| YoY Change | ||
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $2.963M | $1.600M |
| Total Long-Term Liabilities | $0.00 | $0.00 |
| Total Liabilities | $3.882M | $1.600M |
| YoY Change | 142.63% | |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$47.63M | |
| YoY Change | ||
| Common Stock | $96.86M | |
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $49.23M | $8.700M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $53.11M | $10.20M |
| YoY Change | 420.73% |
Cashflow Statement
| Concept | 2018 Q2 | 2017 Q2 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$7.300M | -$4.413M |
| YoY Change | 65.42% | |
| Depreciation, Depletion And Amortization | $195.0K | $100.0K |
| YoY Change | 95.0% | 25.0% |
| Cash From Operating Activities | -$6.460M | -$3.160M |
| YoY Change | 104.43% | 31.12% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | -$760.0K | -$420.0K |
| YoY Change | 80.95% | 162.5% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | ||
| YoY Change | ||
| Cash From Investing Activities | -$760.0K | -$420.0K |
| YoY Change | 80.95% | 162.5% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 0.000 | -20.00K |
| YoY Change | -100.0% | |
| NET CHANGE | ||
| Cash From Operating Activities | -6.460M | -3.160M |
| Cash From Investing Activities | -760.0K | -420.0K |
| Cash From Financing Activities | 0.000 | -20.00K |
| Net Change In Cash | -7.220M | -3.600M |
| YoY Change | 100.56% | 40.08% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$6.460M | -$3.160M |
| Capital Expenditures | -$760.0K | -$420.0K |
| Free Cash Flow | -$5.700M | -$2.740M |
| YoY Change | 108.03% | 21.78% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2018Q2 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
50000 | |
| CY2017Q4 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
50000 | |
| CY2018Q2 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
3464000 | |
| CY2017Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1256000 | |
| CY2017Q4 | us-gaap |
Deposits Assets Current
DepositsAssetsCurrent
|
226000 | |
| CY2018Q2 | us-gaap |
Assets Current
AssetsCurrent
|
49250000 | |
| CY2017Q4 | us-gaap |
Assets Current
AssetsCurrent
|
65065000 | |
| CY2018Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2763000 | |
| CY2017Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1691000 | |
| CY2018Q2 | us-gaap |
Deposit Assets
DepositAssets
|
777000 | |
| CY2018Q2 | us-gaap |
Indefinite Lived Trademarks
IndefiniteLivedTrademarks
|
175000 | |
| CY2017Q4 | us-gaap |
Indefinite Lived Trademarks
IndefiniteLivedTrademarks
|
175000 | |
| CY2018Q2 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
150000 | |
| CY2017Q4 | cue |
Long Term Service Contract Noncurrent
LongTermServiceContractNoncurrent
|
23000 | |
| CY2018Q2 | us-gaap |
Assets
Assets
|
53114000 | |
| CY2017Q4 | us-gaap |
Assets
Assets
|
66954000 | |
| CY2018Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
546000 | |
| CY2017Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1660000 | |
| CY2018Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1124000 | |
| CY2017Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1151000 | |
| CY2018Q2 | cue |
Research And Development Contract Liability Current
ResearchAndDevelopmentContractLiabilityCurrent
|
1218000 | |
| CY2017Q4 | cue |
Research And Development Contract Liability Current
ResearchAndDevelopmentContractLiabilityCurrent
|
2500000 | |
| CY2018Q2 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
75000 | |
| CY2017Q4 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
36000 | |
| CY2018Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
2963000 | |
| CY2017Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
5347000 | |
| CY2018Q2 | cue |
Research And Development Contract Liability Noncurrent
ResearchAndDevelopmentContractLiabilityNoncurrent
|
919000 | |
| CY2018Q2 | us-gaap |
Liabilities
Liabilities
|
3882000 | |
| CY2017Q4 | us-gaap |
Liabilities
Liabilities
|
39231000 | |
| CY2018Q2 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2017Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2018Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
20000 | |
| CY2017Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
19000 | |
| CY2017Q4 | cue |
Common Stock To Be Issued
CommonStockToBeIssued
|
1000 | |
| CY2018Q2 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
96841000 | |
| CY2017Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
94408000 | |
| CY2018Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-47629000 | |
| CY2017Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-32821000 | |
| CY2018Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
49232000 | |
| CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
61607000 | |
| CY2018Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
53114000 | |
| CY2017Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
66954000 | |
| CY2018Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2018Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2018Q2 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2018Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
7644000 | |
| CY2018Q2 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2018Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2018Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
50000000 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
50000000 | |
| CY2018Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
20130766 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
19459194 | |
| CY2018Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
20130766 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
19459194 | |
| CY2018Q2 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
172000 | |
| us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
363000 | ||
| CY2018Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2230000 | |
| CY2017Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
996000 | |
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
11409000 | ||
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
5879000 | ||
| CY2017Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
4413000 | |
| us-gaap |
Operating Expenses
OperatingExpenses
|
15342000 | ||
| us-gaap |
Operating Expenses
OperatingExpenses
|
7763000 | ||
| CY2018Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-7472000 | |
| CY2017Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-4413000 | |
| us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
170000 | ||
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
1000 | ||
| CY2017Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4413000 | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-14808000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-7763000 | ||
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.74 | ||
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.73 | ||
| CY2018Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
20130766 | |
| CY2017Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
10635684 | |
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
20100918 | ||
| us-gaap |
Profit Loss
ProfitLoss
|
-14808000 | ||
| us-gaap |
Profit Loss
ProfitLoss
|
-7763000 | ||
| us-gaap |
Depreciation
Depreciation
|
362000 | ||
| us-gaap |
Depreciation
Depreciation
|
169000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2433000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1250000 | ||
| cue |
Deferred Rent
DeferredRent
|
-39000 | ||
| cue |
Deferred Rent
DeferredRent
|
55000 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
2185000 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
492000 | ||
| us-gaap |
Increase Decrease In Deposits
IncreaseDecreaseInDeposits
|
-551000 | ||
| us-gaap |
Increase Decrease In Deposits
IncreaseDecreaseInDeposits
|
-101000 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-1115000 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
217000 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-27000 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
155000 | ||
| cue |
Increase Decrease In Research And Development Contract Liability
IncreaseDecreaseInResearchAndDevelopmentContractLiability
|
-363000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-16215000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-6620000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1433000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
803000 | ||
| us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
175000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-1433000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-978000 | ||
| cue |
Payments Of Deferred Public Offering Costs
PaymentsOfDeferredPublicOfferingCosts
|
22000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-22000 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-17648000 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-7620000 | ||
| CY2017Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
63584000 | |
| CY2016Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
14976000 | |
| CY2018Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
45936000 | |
| CY2017Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
7356000 | |
| cue |
Accrual Of Deferred Offering Costs
AccrualOfDeferredOfferingCosts
|
159000 | ||
| us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reclassification</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;">Certain amounts previously reported in current liabilities for the prior period have been reclassified to the current period presentation to segregate accounts payable and accrued liabilities to conform with current period presentation. Also, certain amounts previously reported in research and development contract advances have been reclassified to the current period presentation to combine research and development contract advances and prepaid expenses. In addition, certain amounts previously reported as reductions to research and development expenses have been reclassified to collaboration revenue to conform with current period presentation. There was no impact to reported net loss.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reclassifications did not have a material impact on previously reported financial statements.</p></div> | ||
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with U.S.GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Significant estimates include the accounting for revenue recognition, collaboration agreements, potential liabilities, the assumptions utilized in valuing stock-based compensation issued for services, the realization of deferred tax assets, and the impairment of long-lived assets and intangibles. Actual results could differ from those estimates. </p></div> | ||
| us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risks and Uncertainties </p> <p style="margin-top:6pt;margin-bottom:0pt;color:#000000;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company’s operations are subject to a number of factors that may affect its operating results and financial condition. Such factors include, but are not limited to: the Company’s ability to determine candidates for clinical testing, the results of clinical testing and trial activities of the Company’s product candidates, the Company’s ability to obtain regulatory approval to market its product candidates, the Company’s intellectual property, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, the Company’s product candidates if approved for sale, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its product candidates, and the Company’s ability to raise capital. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company currently has no commercially approved product candidates and there can be no assurance that the Company’s research and development programs will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval, as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting its intellectual property. </p></div> | ||
| dei |
Entity Incorporation State Country Name
EntityIncorporationStateCountryName
|
Delaware | ||
| dei |
Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
|
2014-12-31 | ||
| cue |
Number Of Commercial Approved Product Candidates
NumberOfCommercialApprovedProductCandidates
|
0 | ||
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
4637762000 | ||
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
2736591000 | ||
| CY2017Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
7307000 | |
| CY2018Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
45936000 | |
| CY2017Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
7357000 | |
| CY2018Q2 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
3731000 | |
| CY2017Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
2352000 | |
| CY2018Q2 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
968000 | |
| CY2017Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
661000 | |
| us-gaap |
Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
|
0 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0243 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0292 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.00 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
0.820 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
0.834 | ||
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
2732221 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
660600 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
7500 | ||
| CY2018Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
3385321 | |
| CY2018Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
959426 | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
4.07 | |
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
13.87 | ||
| CY2018Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
4.25 | |
| CY2018Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
3.71 | |
| CY2017 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P5Y9M3D | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P4Y9M18D | ||
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P4Y11M23D | ||
| CY2018Q2 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
13598000 | |
| CY2018Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
8105000 | |
| CY2018Q2 | cue |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Of Options Exercisable Intrinsic Fair Value Per Share
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsExercisableIntrinsicFairValuePerShare
|
11.86 | |
| CY2018Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1275000 | |
| CY2017Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
707000 | |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2433000 | ||
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1250000 | ||
| cue |
Number Of Tranches
NumberOfTranches
|
2 | ||
| CY2018Q2 | us-gaap |
Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
|
2500000 | |
| us-gaap |
Description Of Lessee Leasing Arrangements Operating Leases
DescriptionOfLesseeLeasingArrangementsOperatingLeases
|
Upon execution of this lease agreement the Company prepaid three months of rent, two of which will be held in escrow and credited against future rent payments and one month that was applied to the first months rent. The Company also prepaid seven and one half months rent pursuant to an amendment to the license agreement executed on June 18, 2018. These amounts were recorded to deposits and prepaid expenses, respectively at June 30, 2018. | ||
| CY2018Q2 | us-gaap |
Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
|
1517000 | |
| CY2018Q2 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
3577000 | |
| CY2018Q2 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
3967000 | |
| CY2018Q2 | us-gaap |
Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
|
1157000 | |
| CY2018Q2 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
10218000 | |
| CY2018Q2 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
732000 | |
| CY2017Q2 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
438000 | |
| us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
1387000 | ||
| us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
965000 |
